» Articles » PMID: 30798816

Signaling Pathways Regulating Hepcidin

Overview
Journal Vitam Horm
Date 2019 Feb 26
PMID 30798816
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Since its discovery in 2001, there have been a number of important discoveries and findings that have increased our knowledge about the functioning of hepcidin. Hepcidin, the master iron regulator has been shown to be regulated by a number of physiological stimuli and their associated signaling pathways. This chapter will summarize our current understanding of how these physiological stimuli and downstream signaling molecules are involved in hepcidin modulation and ultimately contribute to the regulation of systemic or local iron homeostasis. The signaling pathways and molecules described here have been shown to primarily affect hepcidin at a transcriptional level, but these transcriptional changes correlate with changes in systemic iron levels as well, supporting the functional effects of hepcidin regulation by these signaling pathways.

Citing Articles

Cutaneous leishmaniasis and iron metabolism: current insights and challenges.

Assouab A, Kihel A, Rouahi M, Larribau M, Karim Z, Akarid K Front Immunol. 2024; 15:1488590.

PMID: 39691716 PMC: 11649654. DOI: 10.3389/fimmu.2024.1488590.


A Review of New Concepts in Iron Overload.

Sohal A, Kowdley K Gastroenterol Hepatol (N Y). 2024; 20(2):98-107.

PMID: 38414914 PMC: 10895914.


Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol.

Loveikyte R, Duijvestein M, Mujagic Z, Goetgebuer R, Dijkstra G, van der Meulen-de Jong A BMJ Open. 2024; 14(1):e077511.

PMID: 38296290 PMC: 10828887. DOI: 10.1136/bmjopen-2023-077511.


Distinctive modulation of hepcidin in cancer and its therapeutic relevance.

Lin F, Tuffour A, Hao G, Addai Peprah F, Huang A, Zhou Y Front Oncol. 2023; 13:1141603.

PMID: 36895478 PMC: 9989193. DOI: 10.3389/fonc.2023.1141603.


Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab.

Loveikyte R, Bourgonje A, van der Reijden J, Bulthuis M, Hawinkels L, Visschedijk M Inflamm Bowel Dis. 2023; 29(8):1272-1284.

PMID: 36748574 PMC: 10393210. DOI: 10.1093/ibd/izad010.